Mersana Therapeutics (NASDAQ: MRSN) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $2.75 million versus the consensus estimate of $6.05 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.